Surrozen (SRZN) Revenue & Revenue Breakdown
Surrozen Revenue Highlights
Surrozen Revenue by Period
Surrozen Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $12.50M | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | - |
Surrozen generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Surrozen Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $4.15M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $12.50M | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | - |
Surrozen generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Surrozen Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.69M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| GOSS | Gossamer Bio | - | $95.84M |
| EVLO | Evelo Biosciences | - | - |
| TIL | Instil Bio | - | - |
| REPL | Replimune Group | - | - |
| PCSA | Processa Pharmaceuticals | - | - |
| NLTX | Neurogene | - | - |
| TPST | Tempest Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| ERYP | PHAXIAM Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| SRZN | Surrozen | - | - |
| NEXI | NexImmune | - | - |
SRZN Revenue FAQ
What is Surrozen’s yearly revenue?
Surrozen's yearly revenue for 2023 was $0, representing a decrease of -100.00% compared to 2022. The company's yearly revenue for 2022 was $12.5M, representing an increase of 100.00% compared to 2021. SRZN's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Surrozen’s quarterly revenue?
Surrozen's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). SRZN's quarterly revenue for Q4 2023 was $4.15M, a 100.00% increase from the previous quarter (Q3 2023), and a -66.83% decrease year-over-year (Q4 2022).
What is Surrozen’s revenue growth rate?
Surrozen's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.